Our results show that FLT3 activation triggers the epigenetic activation of TAZ in BP-CML cells, which subsequently interacts with TEAD to elicit TKI resistance. The gene discussed is FLT3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.